Noumed Pharmaceuticals Renews AUD 30 Million OTC Supply Agreement with Australian Pharmacy Chain
Sai Parenterals' Australian subsidiary, Noumed Pharmaceuticals, has renewed a three-year OTC Medicines Supply Agreement with a leading Australian pharmacy chain, valued at AUD 30 million (approximately Rs 204 crore). The deal includes an expanded product portfolio and extended tenure, with plans for new product development and line extensions. Noumed manages manufacturing, regulatory compliance, and distribution, while the pharmacy chain retails products under its brand. The renewal strengthens Noumed's position in the Australian OTC market and complements another recent agreement, bringing the total contracted supply to AUD 232 million.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (74/100). Lens Score 39/100.
Outlets measured: businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (74–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 25 Aug, 02:10 pm. Other outlets followed.